Halozyme Therapeutics (HALO) Misses Q4 EPS by 214c ; Offers Guidance

Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of ($0.24), $2.14 worse than the analyst estimate of $1.90. Revenue for the quarter came in at $451.76 million versus the consensus estimate of $393.92 million.

GUIDANCE:

Halozyme Therapeutics sees FY2026 EPS of $7.75-$8.25, versus the consensus of $8.18. Halozyme Therapeutics sees FY2026 revenue of $1.71-1.81 billion, versus the consensus of $1.76 billion.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.

You May Also Be Interested In

• Raymond James Downgrades Phreesia Inc. (PHR) to Market Perform
• Novartis DM1 drug trial misses primary endpoint in Phase III study
• DA Davidson Downgrades Best Buy (BBY) to Neutral